1887

Abstract

SUMMARY

The influence of the T-lymphocyte-stimulating dipeptide bestatin on the induction of neutralizing antibodies against herpes simplex virus type 1 in the mouse was investigated. dose—response experiments revealed two active ranges from 1 ng/kg to 100 ng/kg and from 10 µg/kg to 10 mg/kg or more. Bestatin (10 mg/kg) enhanced antibody levels after primary infection, if injected between day 5 and day 8 after infection with a maximum effect at day 5. Following secondary infections, bestatin was most effective at day 1 after secondary infection. Moreover, the antibody-generating potency of a formalinized herpes simplex virus type 1 vaccine was elevated considerably. Bestatin and silica seemed to be effective systemically. Treatment of mice with silica before virus infection and additionally with bestatin at day 1 after infection resulted in an additive effect on antibody production. Comparable effects could be obtained when polyinosinic acid. polycytidylic acid or indomethacin was combined with bestatin at day 1. It was assumed that certain factors released by macrophages ‘sensitize’ the antibody-producing system for the enhancing activity of bestatin at day 1. Indeed, culture fluids of macrophages obtained from mice either pretreated with silica or infected by herpes simplex virus were active in enhancing antibody formation upon injection into mice at day 1 in combination with bestatin. Bestatin did not induce interferon activity. No influence of bestatin on the virus content of organs or on mortality was observed.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-65-10-1675
1984-10-01
2022-01-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/65/10/JV0650101675.html?itemId=/content/journal/jgv/10.1099/0022-1317-65-10-1675&mimeType=html&fmt=ahah

References

  1. Allison A. C., Harington J. S., Birbeck M. 1966; An examination of the cytotoxic effects of silica on macrophages. Journal of Experimental Medicine 124:141–154
    [Google Scholar]
  2. Andonov P., Dundarov S., Bakalov B., Tomov S., Zenov N., Todorova R. 1978; The effect of killed antiherpes vaccine. In Proceedings, International Congress on Infectious and Parasitic Diseases (Varna, Bulgaria) p 538
    [Google Scholar]
  3. Bruley-Rosset M., Florentin I., Kiger N., Schulz J., Mathe G. 1979; Restoration of impaired immune functions of aged animals by chronic bestatin treatment. Immunology 38:75–83
    [Google Scholar]
  4. Burns W. H., Billups L. C., Notkins A. L. 1975; Thymus dependence of viral antigens. Nature, London 256:654–656
    [Google Scholar]
  5. Friedman R. M., Vogel S. N. 1983; Interferons with special emphasis on the immune system. Advances in Immunology 34:97–140
    [Google Scholar]
  6. Humes J. L., Bonney R. J., Pelus L., Dahlgren M. E., Sadowski S. J., Kuehl R. A. Jr, Davies P. 1977; Macrophages synthesise and release prostaglandins in response to inflammatory stimuli. Nature, London 269:149–151
    [Google Scholar]
  7. Ishikawa T., Hirokawa V. I., Isurugi K. 1978; Effect of a new immunomodulator, bestatin, in the treatment of urogenital malignancies. Abstracts, XII International Congress on Cancer (Buenos Aires)
    [Google Scholar]
  8. Ishizuka M., Masuda T., Kanbayashi N., Fukasawa S., Takeuchi T., Aoyagi T., Umezawa H. 1980a; Effect of bestatin on mouse immune system and experimental murine tumors. Journal of Antibiotics 33:642–652
    [Google Scholar]
  9. Ishizuka M., Sato J., Sugiyama Y., Takeuchi T., Umezawa H. 1980b; Mitogenic effect of bestatin on lymphocytes. Journal of Antibiotics 33:653–662
    [Google Scholar]
  10. Ishizuka M., Aoyagi T., Takeuchi T., Umezawa H. 1981; Activity of bestatin: enhancement of immune responses and antitumor effect. In Small Molecular Immunomodifiers of Microbial Origin: Fundamental and Clinical Studies of Bestatin pp 17–38 Edited by Umezawa H. Oxford: Pergamon Press;
    [Google Scholar]
  11. Kirchner H. 1978; Suppressor cells of immune reactivity in malignancy. European Journal of Cancer 14:453–459
    [Google Scholar]
  12. Knoblich A., Gortz J., Harle-Grupp V., Falke D. 1983; Kinetics and genetics of herpes simplex virus-induced antibody formation in mice. Infection and Immunity 39:15–23
    [Google Scholar]
  13. Levy H. B. 1977; Induction of interferon in vivo by polynucleotides. Texas Reports on Biology and Medicine 35:91–98
    [Google Scholar]
  14. Muller W. E. G. 1981; Effect of bestatin on DNA and RNA metabolism in T-cells. In Small Molecular Immunomodifiers of Microbial Origin: Fundamental and Clinical Studies oj Bestatin pp 39–58 Edited by Umezawa H. Oxford: Pergamon Press;
    [Google Scholar]
  15. Muller W. E. G., Zahn R. K., Arendes J., Munsch N., Umezawa H. 1979; Activation of DNA-metabolism in T-cells by bestatin. Biochemical Pharmacology 28:3131–3137
    [Google Scholar]
  16. Muller W. E. G., Schuster D. K., Zahn R. K., Maidhof A., Leyhausen G., Falke D., Koren R., Umezawa H. 1982; Properties and specificity of binding sites for the immunomodulator bestatin on the surface of mammalian cells. International Journal of Immunopharmacology 4:393–400
    [Google Scholar]
  17. Nishizawa R., Saino T., Takita T., Suda H., Aoyagi T., Umezawa H. 1977; Synthesis and structure-activity relationship of bestatin analogues, inhibitors of aminopeptidase B. Journal of Medical Chemistry 2d:510–515
    [Google Scholar]
  18. Saito M., Aoyagi T., Umezawa H., Nagai Y. 1977; Bestatin, a new specific inhibitor of aminopeptidases, enhances activation of small lymphocytes by concanavalin A. Biochemical and Biophysical Research Communications 76:526–533
    [Google Scholar]
  19. Snyder D. S., Beller D. J., Unanue E. R. 1982; Prostaglandins modulate macrophage la expression. Nature, London 299:163–165
    [Google Scholar]
  20. Suda A., Aoyagi T., Takeuchi T., Umezawa H. 1976; Inhibition of aminopeptidase B and leucine aminopeptidase by bestatin and its stereoisomer. Archives of Biochemistry and Biophysics 111:196–200
    [Google Scholar]
  21. Trang L. E. 1980; Prostaglandins and inflammation. Seminars in Arthritis and Rheumatism 9:153–189
    [Google Scholar]
  22. Umezawa H. 1981; Small molecular weight immunomodifiers produced by microorganisms: their screening and discoveries and the genetics of microbial secondary metabolites. In Small Molecular Immunomodifiers of Microbial Origin: Fundamental and Clinical Studies of Bestatin pp 1–15 Edited by Umezawa El. Oxford: Pergamon Press;
    [Google Scholar]
  23. Umezawa H., Ishizuka M., Aoyagi T., Takeuchi T. 1976a; Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and Leucine aminopeptidase. Journal of Antibiotics 29:857–859
    [Google Scholar]
  24. Umezawa H., Aoyagi T., Suda H., Hamada M., Takeuchi T. 1976b; Bestatin, a new aminopeptidase B inhibitor produced by actinomycetes. Journal of Antibiotics 29:97–99
    [Google Scholar]
  25. Zisman B., Hirsch M. S., Allison A. C. 1970; Selective effects of antimacrophage serum, silica and antilymphocyte serum on the pathogenesis of herpesvirus infection in young adult mice. Journal of Immunology 104:1155–1159
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-65-10-1675
Loading
/content/journal/jgv/10.1099/0022-1317-65-10-1675
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error